Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2022-12-12 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于成都先导药物开发股份有限公司放弃优先购买权暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a financial institution acting as a sponsor for a company (成都先导药物开发股份有限公司) regarding a specific transaction: the company's waiver of its preemptive rights and related party transaction involving equity investment in a subsidiary (先衍生物技术有限公司). The document includes extensive details on the transaction, parties involved, shareholding structures before and after the transaction, financial data of related entities, legal and procedural compliance, and the sponsor's verification opinion. It is not a general financial report like an annual or interim report, nor is it a brief announcement or voting result. It is a formal audit or verification opinion on a specific transaction, focusing on compliance, fairness, and regulatory adherence. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific transactions, excluding full annual reports. The document length (over 12,000 characters) and detailed content confirm it is a full report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. Q4 2022
2022-12-12 Chinese
成都先导药物开发股份有限公司关于放弃优先认购权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a company's decision to waive its preemptive rights in a capital increase of its associate company, involving related party transactions. It includes comprehensive information about the transaction, the parties involved, shareholding changes, financial data of related entities, board and independent director approvals, and legal compliance statements. The content focuses on a capital/financing update related to shareholding and investment structure changes, rather than a full financial report, earnings release, or regulatory filing. The document length is substantial (9236 characters), and it is not merely an announcement of a report publication or a certification. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-12-12 Chinese
成都先导药物开发股份有限公司关于高级管理人员暨核心技术人员离职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management and core technical personnel at Chengdu Lead Drug Development Co., Ltd. It details the departure of Mr. Wan Jinqiao, his role, the impact of his resignation on the company, and the measures taken by the company to ensure smooth transition. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no mention of shareholder votes or capital changes. The content focuses on management personnel changes, specifically a senior executive leaving the company. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 2411 characters, which is consistent with a typical management change announcement rather than a full report or regulatory filing.
2022-12-12 Chinese
成都先导药物开发股份有限公司关于聘任副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Chengdu Lead Drug Development Co., Ltd. regarding the appointment of a new Vice General Manager, Liu Guansai. It includes details about the board meeting approving the appointment, the qualifications of the appointee, and an attached resume. There is no financial data, no mention of financial results, no regulatory filings about financial performance, and no mention of shareholder votes or dividends. The content focuses solely on management changes, specifically the appointment of a senior executive. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2022-12-12 Chinese
成都先导药物开发股份有限公司独立董事关于第二届董事会第六次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on board meeting proposals, including approval of a related party transaction and appointment of a deputy general manager. It references compliance with company law, governance rules, and board procedures. The content focuses on board/management decisions and opinions rather than financial results, regulatory filings, or shareholder votes. The document length is short (721 characters) and it is not a report or announcement of a report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in board or senior management and related board decisions.
2022-12-12 Chinese
成都先导药物开发股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, total funds used, and references prior announcements and regulatory compliance. It does not contain financial statements or detailed financial analysis but focuses on the company's buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's repurchase of its own shares.
2022-12-01 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.